Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Mohammed Al-Zoubaidi

Vascular Surgery Mount Vernon, IL Medical Doctor

NPI 1063606432 CMS profile 1338248

2 Good Samaritan Way Ste 220, Mount Vernon, IL 62864

Open in the dashboard

General payments

$6,784

92 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Mohammed Al-Zoubaidi of Mount Vernon, IL is reported in the CMS Open Payments database as having received $6,784 across 92 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 58th percentile of Vascular Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $411 17
2024 General $256 3
2023 General $3,739 27
2022 General $315 6
2021 General $186 6
2020 General $144 4
2019 General $1,733 29

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Mohammed Al-Zoubaidi
  • Vascular Surgery median
  • Middle half of Vascular Surgery
  • National median

In program year 2025, general payments to Mohammed Al-Zoubaidi were reported at $411. Among 3,991 Vascular Surgery profiles paid that year, the median was $924 and the middle half received between $273 and $2,636.

Show as a table
Year Mohammed Al-Zoubaidi Vascular Surgery median Middle half National median
2019 $1,733 $796 $226–$2,363 $163
2020 $144 $348 $118–$1,110 $114
2021 $186 $471 $158–$1,421 $132
2022 $315 $725 $222–$2,183 $149
2023 $3,739 $836 $257–$2,440 $160
2024 $256 $909 $252–$2,619 $164
2025 $411 $924 $273–$2,636 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Abbott Laboratories $2,086 15 payments
  2. Boston Scientific Corporation $1,640 11 payments
  3. Bard Peripheral Vascular, Inc. $1,147 18 payments
  4. Endologix, Inc. $386 2 payments
  5. Shockwave Medical, Inc $327 5 payments
  6. Janssen Pharmaceuticals, Inc $184 10 payments
  7. Medtronic Vascular, Inc. $183 3 payments
  8. Penumbra, Inc. $114 1 payment
  9. Inari Medical, Inc. $112 2 payments
  10. Medtronic, Inc. $99 4 payments
  11. Other $507 21 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $3,539 74 payments
  2. Travel and Lodging $3,168 15 payments
  3. Education $78 3 payments
Products named General payments · program years 2019–2025
  1. SUPERA $1,270 8 payments
  2. JETI $590 3 payments
  3. AFX $386 2 payments
  4. Ovation $386 2 payments
  5. Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter $249 4 payments
  6. XARELTO $184 10 payments
  7. IN.PACT Admiral $163 1 payment
  8. Varithena Administration Pack $148 2 payments
  9. Indigo System $114 1 payment
  10. PRESSUREWIRE $112 1 payment
  11. Other $1,760 62 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 1 drug

Part D claims

58

Median for Vascular Surgery: 122

Drug cost

$581

Median for Vascular Surgery: $14,135

Branded share of claims

100%

Median for Vascular Surgery: 71%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Clopidogrel Clopidogrel Bisulfate Brand 58 $581

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 3,087 Part D prescribers listed as Vascular Surgery; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 80 billing codes

Paid by Medicare

$102,521

Of which drugs: $335

Medicare patients

127

Average age 73

Services billed

1,487

56 women, 71 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 51%
Chronic kidney disease 50%
Ischemic heart disease 48%
Diabetes 47%
COPD 38%
Heart failure 33%
Depression 29%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml Q9966 Office 14 1,100 $322
Injection, fentanyl citrate, 0.1 mg J3010 Office 12 14 $11
Injection, midazolam hydrochloride, per 1 mg J2250 Office 11 16 $2

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

92 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Vascular Surgery in Illinois

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record